Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study

Article Infectious Diseases

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Carolina Garcia-Vidal et al.

Summary: The study found that co-infections and superinfections in hospitalized COVID-19 patients were relatively low compared to other viral pandemics. Patients experienced worse outcomes after hospital-acquired superinfections occurred.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Immunology

Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience

Christine A. Vu et al.

Summary: The study evaluated the efficacy of isavuconazole in treating invasive fungal disease and found it to be a promising alternative with high efficacy and safety. The breakthrough rate for invasive fungal disease was 8.5% in patients and 7.8% in courses.

TRANSPLANT INFECTIOUS DISEASE (2021)

添加到收藏夹

Article Immunology

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study

Sara M. Karaba et al.

Summary: Based on the consensus definitions used in the study, bacterial co-infection rates are low in COVID-19 patients, with bacterial respiratory co-infections being rare and urinary tract infections being the most common nonrespiratory infection. The majority of patients had their antibiotic treatments stopped within 48 hours.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

COVID-19 in Lung Transplant Recipients

Jonathan Messika et al.

Summary: The COVID-19 infection in the French cohort of lung transplant patients was severe, with most cases requiring hospitalization and a survival rate of 85.7%. Among the critically ill patients, invasive mechanical ventilation was required for over half, and thrombotic events occurred in 4 patients. Overweight was significantly associated with the risk of death.

TRANSPLANTATION (2021)

添加到收藏夹

Review Immunology

COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?

Robin K. Avery

Summary: Therapeutic interventions for solid organ transplant (SOT) recipients with COVID-19 have evolved over two main eras during the pandemic: early era and later era. Initially, drugs like hydroxychloroquine, lopinavir-ritonavir, and tocilizumab were widely used, but later remdesivir, dexamethasone, and convalescent plasma became more common along with a variety of investigational and repurposed agents.

TRANSPLANTATION (2021)

添加到收藏夹

Article Immunology

Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients

Lauren Fontana et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Immunology

Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients

Nitipong Permpalung et al.

TRANSPLANTATION (2020)

添加到收藏夹

Article Immunology

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

J. Peter Donnelly et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Surgery